

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

What is claimed is:

1. (Cancelled).
2. (Cancelled).
3. (Cancelled).
4. (Original) A crystalline form of anhydrous form 1 of (2S,4S)-4-fluoro-1-[4-fluoro- β -(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile *p*-toluenesulfonic acid salt characterized by a powder x-ray diffraction pattern comprising at least one of the following peaks:

Two theta (deg)*	d-spacing (angstroms)
6.1 \pm 0.2	14.4 \pm 0.5
6.4 \pm 0.2	13.9 \pm 0.5
7.7 \pm 0.2	11.5 \pm 0.3
22.2 \pm 0.2	4.0 \pm 0.1
24.7 \pm 0.2	3.6 \pm 0.1

* Using copper K-alpha 1 radiation.

5. (Original) The crystalline form of claim 4 comprising two or more of the following peaks:

Two theta (deg)*	d-spacing (angstroms)
6.1 \pm 0.2	14.4 \pm 0.5
6.4 \pm 0.2	13.9 \pm 0.5
7.7 \pm 0.2	11.5 \pm 0.3
22.2 \pm 0.2	4.0 \pm 0.1
24.7 \pm 0.2	3.6 \pm 0.1

* Using copper K-alpha 1 radiation.

6. (Cancelled).
7. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim [[1]] 4.
8. (Cancelled).
9. (Cancelled).
10. (Cancelled).
11. (Cancelled).
12. (Previously Presented) The pharmaceutical composition as claimed in claim 7 further comprising one or more pharmaceutically acceptable carrier, diluent, or excipient.
13. (Cancelled).
14. (Cancelled).
15. (Cancelled).